For the best experience on the Abcam website please upgrade to a modern browser such as Google Chrome
Factor VII Human Chromogenic Activity Assay Kit (ab108830) has been developed to determine human FVII activity in plasma, serum and cell culture supernatants. The assay couples immunofunctional and indirect amidolytic assay. A polyclonal antibody specific for Human FVII has been pre-coated onto a microplate and active FVII is bound to the immobilized antibody. The assay measures the ability of lipoprotein TF/FVIIa to activate factor X (FX) to factor Xa. The amidolytic activity of the TF/FVIIa complex is quantitated by the amount of FXa produced using a highly specific FXa substrate releasing a yellow para-nitroaniline (pNA) chromophore. The change in absorbance of the pNA at 405 nm is directly proportional to the FVII enzymatic activity.
Factor VII (FVII) is a vitamin K-dependent plasma glycoprotein that is synthesized in the liver and circulates in blood as a single-chain inactive zymogen with a molecular mass of 50 kDa. Upon tissue damage and vascular injury, the cell surface receptor and cofactor tissue factor (TF) binds and allosterically activates FVII to its active form, FVIIa. The TF/FVIIa complex catalyzes the conversion of both factor IX to factor IXa and factor X to factor Xa to initiate coagulation via the extrinsic pathway. Very low levels of FVII are associated with severe coagulation disorders. Elevated plasma levels of FVII coagulant activity constitute an independent risk factor for fatal outcomes of coronary heart disease in middle-aged men.
|10X Diluent M Concentrate||1 x 20ml|
|20X Wash Buffer Concentrate||1 x 30ml|
|Assay Diluent||1 x 30ml|
|FXa Substrate||2 units|
|Human FVII Microplate||1 x 96 units|
|Human FVII Standard||1 unit|
|Human FX||1 unit|
|rhTF (lipoprotein)||1 unit|
|Sealing Tapes||3 units|
Our Abpromise guarantee covers the use of ab108830 in the following tested applications.
|Functional Studies||Use at an assay dependent dilution.|
ab108830 has not yet been referenced specifically in any publications.